partneringNEWS

Epizyme: Intensive dealmaking in pursuit of personalized therapeutics

ctheodoropulos — Tue, 01 May 2012 19:25:30 +0000

Little was known about the branch of epigenetics called histone methyltransferases (HMTs) when Epizyme began in late 2007. Yet before the company presented the world's first animal demonstration of efficacy for HMTs in July 2011, it had already attracted USD 54 million in venture investment and USD 45 million in funding from two pharma partners and two foundations. Read more »

Forma Therapeutics: Structured acquisitions to fix broken biotech model

Forma Therapeutics: Structured acquisitions to fix broken biotech model

jbrosky — Tue, 01 May 2012 19:25:18 +0000

In January this year, Forma Therapeutics announced two conventional agreements for assets spinning out of its innovative discovery platform that aim for high-risk targets but hold high-reward valuations, potentially totaling USD 1.45 billion in milestone payments. Read more »

Foundation Medicine: Molecular information disrupting the oncology universe

ctheodoropulos — Tue, 01 May 2012 19:25:05 +0000

The news from Foundation Medicine could not be more encouraging for the company, nor more disruptive for the universe of oncology as we know it today. Read more »

Joslin Diabetes Center: Building “collaboratories” for diabetes solutions

ctheodoropulos — Tue, 01 May 2012 19:24:50 +0000

John Brooks has lit a fire under the Joslin Diabetes Center. Over the past year a string of announcements has flowed from the traditionally understated 114-year-old institution. Read more »

BIO.NRW: Showcasing “the center” of biotech at BIO-Europe^® 2011

EU medtech management and oversight: New, but complex, proposals

ctheodoropulos — Thu, 19 Apr 2012 23:59:46 +0000

A clear, transparent, single mechanism for the oversight and coordination of medtech rules is needed to restore confidence in the European medtech regulatory system which has been badly undermined by recent product safety scandals. Read more »

No related posts.

Inova Software: Structuring business development to align with strategy

jbrosky — Wed, 11 Apr 2012 15:10:45 +0000

Opportunities for acquiring external assets may move faster than an internal BD group can react. Inova supports a capability to be both fast and nimble in the hunt for novel assets from scouting through to licensing and beyond to alliance management. Read more »

GSK, J&J back USD 200 million fund for early stage assets

jbrosky — Sun, 25 Mar 2012 13:08:00 +0000

The chairmen of Johnson & Johnson Pharmaceuticals and GlaxoSmithKline R&D announced a trailblazing venture fund for fast-tracking early stage assets during the closing plenary session at BIO-Europe Spring^® in Amsterdam. Read more »

Investors more confident, but selective with biotechs

jbrosky — Sun, 25 Mar 2012 13:07:39 +0000

The biotech sector continues to outperform other industries in public equity markets in the United States, but private equity is more selective about opportunities, according to Biotechnology Industry Organization (BIO). Read more »

Examining major deals of 2011 with the real dealmakers

ctheodoropulos — Thu, 22 Mar 2012 00:29:11 +0000

Lead executives with four of the headline-grabbing deals of the past year shared insights into the negotiation with participants at BIO-Europe Spring^® in Amsterdam. Read more »

Barcelona to welcome BIO-Europe Spring® 2013

ctheodoropulos — Wed, 21 Mar 2012 13:45:01 +0000

The Catalonia biotech sector has developed rapidly in the two years since BIO-Europe Spring^® last visited Barcelona. Major infrastructure has come online, and companies in a start-up phase have now matured in asset development and are ready to partner internationally. Read more »

partneringNEWS

Epizyme: Intensive dealmaking in pursuit of personalized therapeutics

Related Posts

Forma Therapeutics: Structured acquisitions to fix broken biotech model

Related Posts

Foundation Medicine: Molecular information disrupting the oncology universe

Related Posts

Joslin Diabetes Center: Building “collaboratories” for diabetes solutions

Related Posts

EU medtech management and oversight: New, but complex, proposals

Related Posts

Inova Software: Structuring business development to align with strategy

Related Posts

GSK, J&J back USD 200 million fund for early stage assets

Related Posts

Investors more confident, but selective with biotechs

Related Posts

Examining major deals of 2011 with the real dealmakers

Related Posts

Barcelona to welcome BIO-Europe Spring® 2013

Related Posts